Managing the generalised tonic-clonic seizure and preventing progress to status epilepticus: A stepwise approach

Internal Medicine Journal

Volumn 43, Issue 7, 2013, Pages 739-746

  Dionisio, S ^a   Brown, H ^a   Boyle, R ^a   Blum, S ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anticonvulsant; Epilepsy; Seizure; Status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; HARKOSERIDE; IMMUNOGLOBULIN; KETAMINE; LORAZEPAM; MAGNESIUM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PROPOFOL; STEROID; THIOPENTAL; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; BLOOD BRAIN BARRIER; BRONCHODILATATION; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; DEPRESSION; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INDUCED HYPOTHERMIA; INTENSIVE CARE; KETOGENIC DIET; LACTIC ACIDOSIS; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STEROID THERAPY; THROMBOPHLEBITIS; TONIC CLONIC SEIZURE;

ANTICONVULSANT; EPILEPSY; SEIZURE; STATUS EPILEPTICUS;

ANIMALS; ANTICONVULSANTS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; SEIZURES; STATUS EPILEPTICUS;

EID: 84880345798     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12168     Document Type: Review

References (54)

1. Shorvon S. Clinical trials in acute repetitive seizures and status epilepticus. Epileptic Disord 2012; 14: 138-147.
2. DeLorenzo RJ, Garnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton L etal. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia 1999; 40: 164-169.
3. Waterhouse EJ, Garnett LK, Towne AR, Morton LD, Barnes T, Ko D etal. Prospective population-based study of intermittent and continuous convulsive status epilepticus in Richmond, Virginia. Epilepsia 1999; 40: 752-758.
4. Shorvon S. Handbook of Epilepsy Treatment, 3rd edn. Oxford: Wiley-Blackwell; 2010.
5. Friedman A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg. Epilepsia 2011; 52(Suppl 8): 19-20.
6. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005; 25: 7724-7733.
7. Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci 2005; 25: 5511-5520.
8. Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazipine and ZN2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997; 17: 7532-7540.
9. Bell DM, Richards G, Dhillon S, Oxley JR, Cromarty J, Sander JW etal. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991; 10: 183-190.
10. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y etal.; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591-600.
11. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol 2011; 259: 643-648.
12. Walker M. Status epilepticus: an evidence based guide. BMJ 2005; 331: 673-677.
13. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249: 1452-1454.
14. Comer WH, Giesecke AH. Injectable Lorazepam. Semin Anesth 1982; 1: 33-39.
15. Eadie M, Vajda F. Antiepileptic Drugs Pharmacology and Therapeutics. Vol. 138. Berlin, Heidelberg: Springer Publishing; 1999.
16. Shorvon SD. The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia 1998; 39: S15-23.
17. Treiman DM etal. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339: 792-798.
18. Trinka E. The use of valproate and new antiepileptic drugs in status epilepticus. Epilepsia 2009; 50(Suppl 12): 49-51.
19. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000; 41: 1342-1345.
20. Surges R, Volynski KE, Walker MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 2008; 1: 13-24.
21. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations-Have newer agents altered clinical outcomes. Epilepsy Res 2012; 98: 194-198.
22. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006; 47: 469-478.
23. Walker M. Status epilepticus: an evidence based guide. BMJ 2005; 331: 673-677.
24. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012; 21: 233-236.
25. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on levetiracetam. Ther Adv Neurol Dis 2009; 2: 79-91.
26. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH etal. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588-589.
27. Gamez-Leyva G, Aristin JL, Fernandez E, Pascual J. Experience with intravenous levetiracetam in status epilepticus: a retrospective case series. CNS Drugs 2009; 23: 983-987.
28. Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15: 467-469.
29. Bilo L, Meo R, Fulvia de Leva M. Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda. Clin Drug Invest 2006; 26: 357-359.
30. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006; 15: 214-218.
31. Memtt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938; 111: 1068-1073.
32. Sperk G, Wieser R, Widmann R, Singer EA. Kainic acid induced seizures: changes in somatostatin, substance P and neurotensin. Neuroscience 1986; 17: 1117-1126.
33. Liu H, Mazarati AM, Katsumori H, Sankar R, Wasterlain CG. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci USA 1999; 96: 5286-5291.
34. Mazarati A, Liu H, Wasterlain C. Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience 1999; 89: 167-173.
35. Sloviter RS. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia 1999; 40(Suppl 1): S34-39.
36. Rossetti AO. Which anesthetic should be used in the treatment of refractory status epilepticus. Epilepsia 2007; 48(Suppl 8): 52-55.
37. Shorvon SD, Baulac TM, Cross H, Trinka E, Walker M; TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008; 49: 2177-2184.
38. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134: 2802-2818.
39. Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004; 45: 757-763.
40. Kramer AH. Early ketamine to treat refractory status epilepticus neurocrit care. Neurocrit Care 2012; 16: 299-305.
41. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology 1998; 51: 1765-1766.
42. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure 2011; 20: 723-726.
43. Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008; 82: 219-222.
44. Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011; 258: 218-222.
45. Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 2012; 98: 232-237.
46. Blumkin L, Lerman-Sagie T, Houri T, Gilad E, Nissenkorn A, Ginsberg M. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol 2005; 20: 239-241.
47. Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia 2010; 51: 2207-2210.
48. Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011; 52: e148-152.
49. Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ. The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011; 14: 348-353.
50. Walker MC. The potential of brain stimulation in status epilepticus. Epilepsia 2011; 52(Suppl 8): 61-63.
51. Nam SH, Lee BL, Lee CG, Yu HJ, Joo EY, Lee J etal. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia 2011; 52: e181-184.
52. Corry JJ, Dhar R, Murphy T, Diringer MN. Hypothermia for refractory status epilepticus. Neurocrit Care 2008; 9: 189-197.
53. Goldberg EM, Taub KS, Kessler SK, Abend NS. Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child. Neuropediatrics 2011; 42: 188-190.
54. Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995; 37: 682-688.